Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral iQ-007 in Healthy Male and Female Adult Participants

NCT06899230 is registered in ClinicalTrials.gov with iQure Australia Pty Ltd as lead sponsor.

NCT NCT06899230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06899230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral iQ-007 in Healthy Male and Female Adult Participants
Lead sponsor
iQure Australia Pty Ltd
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 8, 2025
Completion date
January 29, 2026
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistant epilepsy, focal seizure